Eric Matthews

Mr. Matthews has more than 20 years of experience in biopharmaceuticals in roles spanning global product strategy, marketing, and product development as well as US marketing and sales leadership. Over his career, he has launched 15 new medicines, including Avastin®, Tarceva®, Tecentriq®, and Imfinzi®. Prior to joining Arcus, Mr. Matthews was with AstraZeneca and Roche/Genentech where he worked on first-in-class immunotherapy products and novel therapeutic combinations. He has also worked as a Congressional Health Policy Analyst and was involved in developing the Medicare Modernization Act.